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ABSTRACT 
 
Size, Solubility, and the Serotonin-gated Ion Channel Receptor: In Search of an 
Improved Extracellular Domain Model. (April 2009) 
Emily Sarah Weiss 
Department of Biochemistry/Biophysics 
Texas A&M University 
 
Research Advisor: Dr. Gregg B. Wells 
Department of Molecular and Cellular Medicine 
 
The 5-HT3 receptor (5-HT3R) is the only serotonin receptor that is not a G-coupled 
protein receptor.  It has been implicated as a contributor to cytotoxic drug-evoked 
emesis, irritable bowel syndrome, pruritis, schizophrenia, Parkinson disease, addiction, 
bulimia, nociception, and problems with cognitive function.  It follows that improved, 
more specific 5-HT3R antagonists are an attractive goal for the pharmaceutical industry.  
Current models of the 5-HT3R are based on homology to the highly structurally related 
and well studied nicotinic acetylcholine receptor, but no high resolution image of the full 
length 5-HT3R has yet been determined.  This research works towards development of 
an extracellular domain model, which would be a better candidate for x-ray 
crystallography and NMR spectroscopy due to its higher water solubility and smaller 
size.  Constructs of the mouse 5-HT3R were made with an N-terminal mAb-142 epitope 
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tag for immunoblotting with a linker region to promote flexibility of the tag in the 
extracellular domain.  A Kozak sequence was incorporated to optimize expression in 
Xenopus oocytes.  Designs included a full length construct; a construct truncated after 
the first transmembrane domain with valine substituted for an intra-membrane aspartic 
acid residue; and constructs terminated after the extracellular domain, after the first 
transmembrane domain, and directly preceding the third transmembrane domain.  
Binding assays with [3H]-granisetron showed significant binding only with the full 
length construct, though minimal binding was observed with the construct with the 
valine substitution.  These results suggest that elements present in the other parts of the 
native receptor may be vital to efficient ligand binding and should be included in the 
design of a successful truncated model. 
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CHAPTER I 
INTRODUCTION: THE 5-HT3A RECEPTOR AS A TARGET FOR 
THERAPEUTIC AGENTS 
 
Ionotropic receptors are ligand-gated ion channels (LGICs) that respond to the binding 
of neurotransmitters such as acetylcholine (ACh), 5-hydroxytryptamine (5-HT3), 
glycine, or γ-aminobutyric acid (GABA).  Binding of the appropriate ligand causes an 
increased probability of conformational change of the receptor, channel opening, and the 
exchange of specific ions across the membrane.  The generation of a membrane potential 
depends upon changes of ion concentrations across the membrane; LGICs are, therefore, 
vital to rapid chemical transmission of nerve impulses. 
 
Structure and classification of the 5-HT3R 
The Cys-loop superfamily of LGICs consists of both anionic-selective inhibitory 
receptors which cause hyperpolarization of the membrane (including those activated by 
 
 
GABA or glycine) and cation-selective excitatory receptors which cause depolarization 
of the membrane (including those activated by ACh or 5-HT3).  Members of this 
superfamily of receptors share several distinguishing features.  The five protein subunits 
that compose a Cys-loop receptor are arranged about a central pore which is permeable 
_______________ 
This thesis follows the style of Journal of Biological Chemistry. 
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to ions.  Relative permeability of sodium, potassium, and calcium vary depending on the 
specificity of the individual receptor.   
 
Each subunit has a ligand-binding N-terminal extracellular domain (ECD) containing a 
characteristic thirteen residue sequence.  This sequence is bordered on either side by 
cysteine residues, which form a disulfide bond and create a closed loop localized 
between the binding and channel domains (1).  The channel domain consists of four 
transmembrane spanning helices (designated M1-M4), with M2 lining the pore and M1, 
M3, and M4 comprising the outer helices (2).  Cys-loop receptors are widely dispersed 
throughout the central and peripheral nervous systems.  Because of the quantity of 
unique subunits and their ability to co-assemble with numerous subunits in a variety of 
different pentamers, ligand binding properties and pharmacological profiles of Cys-loop 
receptors are incredibly diverse. 
 
The cation-selective Cys-loop receptors 
There are at least seven serotonin (5-HT) receptor subclasses, but the 5-HT3 receptors 
(5-HT3Rs) are the only type which are LGICs; the others are G-protein coupled 
receptors, which are not classified as part of the Cys-loop superfamily (3).  The most 
widely studied family of the Cys-loop superfamily is that of the nicotinic acetylcholine 
receptor (nAChR).  These LGICs open in response to nicotine as well as to ACh.  
NAChR research has been favored because of the general biological availability of the 
nAChR through isolation of muscle-type nAChR from Torpedo ray, the fairly recent 
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discovery of ACh binding protein (AChBP), a protein with a homologous extracellular 
domain to that of the nAChR, and the discovery of a wide range of snake toxins which 
aid in the purification of nAChRs (Figure 1).  The structure of the 5-HT3Rs, on the other 
hand, is not resolved at a high resolution, though it is widely accepted to be similar to 
that of the nAChR.  Various homology models have been proposed (4).  
 
 
  
 
FIGURE 1.  Model of AChBP.  Model generated in PyMol from 2.7 Å X-ray crystallography structure of 
AChBP (Protein Data Bank entry DOI 10.2210/pdb1i9b/pdb).  
 
 
 
 
Classes of 5-HT3Rs 
Two 5-HT3R subunits (subunits A and B) have been characterized most thoroughly.  The 
5-HT3A subunits assemble as homopentamers, and also as heteropentamers with the 5-
HT3B subunit, which does not itself form homopentamers (5).  The 5-HT3C, 5-HT3D,and 
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5-HT3E subunits have recently been found to form heteropentamers with the 5-HT3A 
subunit, but these heteropentamers do not exhibit markedly different pharmalogical 
profiles than that of 5-HT3A homopentamers (6).  The 5-HT3A receptor can also assemble 
with some nAChR subunits to form heteromeric receptors.  Combining 5-HT3A subunits 
with the nAChR α4 subunit produces a particularly novel heteropentamer with increased 
calcium ion permeability and reduced sensitivity to the antagonist tubocurarine (7). 
 
Distribution and therapeutic targeting 
5-HT3A receptor subunit mRNA has been discovered in numerous brain regions and in 
the small intestine, colon, spleen, thymus, and prostate (8).  In addition, 5-HT3AB 
receptors are expressed in many cells of the immune system, pointing to a possible role 
in inflammation (9).  5-HT3B receptor subunit mRNA is less ubiquitous, but has been 
detected primarily in brain and kidney by Northern blot analysis (10).  5-HT3R 
concentration is highest in the brain regions (especially the brain stem) but is also 
significant in the gastrointestinal tract where the receptors contribute to regulation of the 
enteric nervous system (11).   
  
Associated pathologies 
5-HT3Rs have been implicated in a wide variety of disorders.  The mechanism of 
radiation-induced emesis involves the release of serotonin and its direct effect upon the 
5-HT3R (12).  This mechanism has led to the use of 5-HT3R antagonists as a treatment 
for the adverse side effects of chemotherapy, as well as for nausea and vomiting due to 
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surgery or pregnancy.  It has been proposed that the 5-HT3R boasts a role in the 
mediation of inflammatory pain, making pharmaceutical studies of antagonists as 
nociceptives similarly attractive (13).  The G-protein coupled 5-HT receptors have been 
associated with an vast variety of behavioral disorders such as general anxiety disorders, 
social phobias, obsessive-compulsive disorders, panic disorders, and post traumatic 
stress disorders (14).  5-HT3 antagonists in particular have anti-psychotic effects in 
patients with Parkinson disease and improve p50 gating in schizophrenics (15-18).  
Irritable bowel syndrome may be caused in part by abnormal function of 5-HT3Rs, but 
antagonists have only been an effective treatment in women (19).  In addition, the 5-
HT3R possesses a significant role in cognitive function, and there is some evidence that 
antagonists could be helpful in the treatment of addiction, bulimia, and pruritis (18).  
Taking into account the myriad of disorders associated with the 5-HT3R, it is not 
difficult to appreciate the advantages presented by fully understanding the workings of 
the 5-HT3R and designing antagonists with better selectivity and activity. 
 
Models of the 5-HT3R 
The most definitive breakthroughs in the field of Cys-loop receptor research have come 
through the discovery and isolation of AChBP from the freshwater snail Lymnaea 
stagnalis.  AChBP is a water-soluble homopentamer with ACh binding sites and has 
subunits featuring a twelve-membered Cys-loop (instead of thirteen-membered) and 
similar size and shape to the ECD of the Torpedo nAChR.  Since its structure was first 
determined by x-ray crystallography in 2001, crystal structures of AChBP at numerous 
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resolutions in the range of 2.9 Å and with various ligands bound to the active site have 
been visualized (20-24).   
 
Another breakthrough was the electron microscopy of the Torpedo ray muscle nAChR.  
Though the resolution of this image was only 4 Å, the spatial relationships between the 
binding and channel domains, the protein backbone, and the locations of α-carbon atoms 
and bulky side chains were ascertained (2).  Recently, the first atomic resolution crystal 
structure of a monomeric nAChR ECD at a resolution of 1.94 Å has been determined 
(25).   
 
Modeling of the 5-HT3R at this point is based solely on homology to elucidated 
structures of AChBP and nAChRs; a high resolution image of the 5-HT3R itself is yet to 
be obtained.  Discovering more detail about the structure and function of the 5-HT3R and 
its subunits would facilitate the design of novel therapeutic agents and promote more 
refined treatments for the considerable number of 5-HT3R-related pathologies. 
 
Benefits of an ECD model 
One strategy to further illuminate the structure of the 5-HT3R is to develop a model 
which is more water soluble.  A more water soluble protein will crystallize more easily 
and therefore be a better candidate for x-ray crystallography.  Wells et. al have 
underscored the utility of creating an ECD model of the nAChR, which, because of its 
shorter length, would additionally be a better candidate for nuclear magnetic resonance 
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spectroscopy (NMR) (26).  Though various ECD models of nAChRs have been 
produced, they have been limited in simulating ligand binding affinities and subunit 
assembly.  An ECD model that more closely reflects the properties of the full-length 
receptor remains a very attractive objective for both the nAChR and the 5-HT3R. 
 
Illuminating the role of M1 
The presence of M1 is necessary for efficient expression of extracellular α7 nAChRs 
(27) as well as for α4β2 nAChRs (26).  It has been proposed that M1 functions primarily 
as a tether (28), but roles in surface trafficking (29) and channel gating(30) in nAChRs 
and as a primary determinant of desensitization kinetics in 5-HT3Rs (31) have also been 
proposed.   
 
This study probes the importance of M1 in efficient functioning of extracellular 5-
HT3Rs.  The role of an atypical hydrophilic residue present in M1 is explored.  
Elucidating the function of M1 in the 5-HT3A receptor subunit will aid in the creation of 
a more representative truncated model of the 5-HT3R. 
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CHAPTER II 
METHODS 
 
Construction of 5-HT3A DNA plasmids 
Primer design 
Sequences were introduced into plasmids using modified QuikChange PCR.  Point 
mutations and additions of three or fewer bases were incorporated into primers and 
plasmids using a standard QuikChange mutagenesis procedure. 
 
Description of constructs 
The Xenopus Kozak sequence (ACC) was inserted directly before the start codon of the 
sequence coding for the mouse full length 5-HT3A subunit in the pSP64 poly(A) plasmid 
(32).  The starting full length construct, a gift from David Julius, originally contained 
two copies of the mAb 142 epitope at the C-terminus.  Using two rounds of modified 
QuikChange PCR, an N-terminus mAb 142 epitope (QVTGEVIFQTPLIKNP) 
surrounded on either side by a linker region (consisting of 6 repeats of alanine, guanine, 
and serine) was inserted into the ECD (33).  DNA sequences were optimized for 
expression using GeneDesign 2.0 and the codon usage table for Xenopus laevis.  To halt 
the translation of the two C-terminal epitope tags, the first base pair of the first tag was 
mutated to a uracil, generating a UAA stop codon.  This construct was designated 5-
HT3Full.   
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The 5-HT3M1, 5-HT3ECD, and 5-HT3M1M2 constructs were derived from the 5-
HT3Full construct using PCR mutagenesis.  To produce the 5-HT3M1 construct, a stop 
codon was inserted two amino acids after the end of the first transmembrane domain. 
The 5-HT3ECD construct was produced by insertion of a stop codon directly before the 
start of M1.  The 5-HT3M1M2 construct was produced by insertion of a stop codon 
directly preceding the third transmembrane domain.  The 5-HT3970V construct was 
derived from the 5-HT3M1 construct and contained a substitution of an aspartic acid 
residue in the interior of M1 to a valine residue (Figure 2).  Primers for PCR 
mutagenesis were ordered from Invitrogen, subjected to PAGE purification, and 
reconstituted at a concentration of 20 pmol/µl (Table 1). 
 
PCR 
PCR with AccuPrime™  Pfx DNA polymerase (Invitrogen) was carried out using 10 ng 
of template DNA, 50 picomoles of each primer, and 5 µl AccuPrime™ Pfx Reaction 
Mix.  After denaturation for 3 minutes at 95°C, the reaction tube underwent 25 cycles of 
denaturation at 95°C for 1 minute, annealing at 53-68°C for 1 minute, and extension at 
72°C for 10 minutes. 
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FIGURE 2. Schematics of 5-HT3R construct design.  The Kozak fragment (purple) directly precedes the 
ECD (teal).  Each linker region (maroon) consists of alanine, guanine, and serine (repeated 6 times).  The 
mAb 142 epitope binding region (magenta) is between 2 linker AGS repeat regions.  The transmembrane 
segments (orange) are situated between other coding segments (olive).  The location of inserted stop 
codons for various constructs is indicated.  Valine has been substituted for an aspartic acid residue as 
shown in 5HT3970V. 
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TABLE 1 
Primers for creation of 5HT3A constructs 
Adding 
Xenopus 
Kozak 
fragment 
FORWARD:  
5’- GAATACAAGCTTGCCACCATGCGGCTCTGCATCCCGCAGGTGC -3’ 
REVERSE: 
5’- GATGCAGAGCCGCATGGTGGCAAGCTTGTATTCTATAGTGTCACC -3’ 
First linker 
and first half 
of mAb 142 
epitope tag 
FORWARD: 
5’- TCTGCTGGATCTGCAGGTTCAGCCGGATCCCAAGTGACAG 
GAGAAGTTATCTTTACCCAGCCTGCTCTACTAAGGCTGTCAGAC-3’ 
REVERSE: 
5’- GGATCCGGCTGAACCTGCAGATCCAGCAGAACCAGCACTT 
CCGGCACTCCCAGCGGTATCTCGGGCCTGGGTGGCCCTCCTCCG-3’ 
Second half of 
mAb 142 
epitope tag 
and second 
linker 
FORWARD:  
5’-GCAGGGAGCGCCGGCAGCGCAGGATCAGCAGGCTCCGCTGG 
TAGCGCTGGCTCTACCCAGCCTGCTCTACTAAGGCTGTCAGAC-3’ 
REVERSE: 
5’- TGCTGATCCTGCGCTGCCGGCGCTCCCTGCAGGGTTCTTAATCA 
ATGGAGTCTGAAAGATAACTTCTCCTGTCACTTGGGATCC-3’ 
Removing C-
terminal 2x 
mAb 142 
epitope 
FORWARD:  
5-GGCATTATTCTACGCGTTAAGTAACAGGAGAAGTAATCTTCC-3’ 
REVERSE: 
5’-CTTCTCCTGTTACTTAACGCGTAGAATAATGCCAAATGGACC-3’ 
5-HT3 M1 FORWARD: 
5’-CTGCCCCCGGACAGTTGAGAGAGAGTCTCTTTCAAGATCACAC-3’ 
REVERSE: 
5’-GAAAGAGACTCTCTCTCAACTGTCCGGGGGCAGGCAAAAGCCC-3’ 
5-HT3 M1M2 FORWARD: 
5’-GCCATCGGTACCTAACCCCTCATTGGTGTCTACTTTGTGG-3’ 
REVERSE: 
5’- ACACCAATGAGGGGTTAGGTACCGATGGCCGTTGCCGGCAG-3’ 
5-HT3 ECD FORWARD: 
5’-ATCCGCCGGAGGTAGCCTTTATTCTATGCAGTCAGCCTCTTGC-3’ 
REVERSE: 
5’- CATAGAATAAAGGCTACCTCCGGCGGATGATCACGTAGAAC-3’ 
5-HT3 970V FORWARD: 
5’-TCCTCATGGTCGTGGTCATTGTGGGCTTTTGCCTGCCCCCG-3’ 
REVERSE: 
5’-CAAAAGCCCACAATGACCACGACCATGAGGAAGATACTGGG-3’ 
 
 
PCR product purification 
The PCR product was run at 97 volts on a 1% agarose gel containing 1µL/mL ethidium 
bromide at room temperature in 1X TAE buffer.  Correct PCR product was selected and 
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digested at 37°C with Dpn I for 2 hours to degrade parent DNA.  After heat inactivation 
at 80°C for 20 minutes, the product was run on a 1% agarose gel under the above 
mentioned conditions.  The desired band was extracted using the Zymoclean Gel DNA 
Recovery Kit. 
 
Bacterial transformation 
One Shot OmniMAX 2 T1 Phage-Resistant Cells (Invitrogen) were incubated for 30 
minutes with 2 µl of DNA product after thawing on wet ice for 30 minutes.  They were 
heat shocked for 1 minute at 42°C and placed on ice again for 5 minutes.  After shaking 
at 225 rpm for 30 minutes at 37°C in LB medium, the bacterial solution was centrifuged 
at 14000 rpm for 2 minutes.  The bacterial pellet was resuspended in 50 µL of LB 
containing 0.5 µL of ampicillin.  Dilutions of 1:1, 1:10, and 1:100 of the reaction were 
spread onto LB plates containing ampicillin and grown at 37°C overnight. 
 
Purification and isolation of DNA 
Colonies were selected and added to 2-3 mL of LB containing 2-3 µL ampicillin and 
grown overnight.  DNA was isolated and purified using the Zyppy Plasmid Mini-prep 
procedure.  Double digests were performed with EcoRV and Xho I at 37°C with Buffer 
3 + BSA to confirm presence of correct plasmid.  After sequencing, a colony known to 
contain the correct plasmid was chosen from a bacterial stock plate and added to a flask 
containing 200 mL of LB and 200 µL ampicillin; the bacteria was grown overnight, and 
DNA was isolated using the QIAGEN Plasmid Midi-Prep Kit.  Double and single 
  13 
digests were performed with EcoRV and/or Xho I to confirm presence of correct DNA 
and to determine concentration. 
 
Expression of protein in Xenopus oocytes 
Ten µg of DNA was linearized by incubation for 3 hours with EcoRI at 37°C and 
recovered via a phenol/chloroform extraction and ethanol precipitation.  RNA was 
produced from linearized DNA using an SP6 mMessage mMachine Kit and recovered 
through phenol/chloroform extraction and precipitation with isopropanol.  The product 
was verified by running on a 1% agarose gel. 
 
Xenopus laevis were obtained from NASCO (Fort Atkinson, WI) and cared for in a 
manner approved by the Institutional Animal Care and Use Committee of Texas A&M 
University.  After removal from the frog by survival surgery, oocytes were rinsed with 
calcium-free OR2, defolliculated with collagenase 1A, and rotated gently to aid in 
separation.  After rinsing in Leibovitz’s L- glutamine medium powder (L-15) + HEPES, 
oocytes were stored in L-15 at 19°C until injection. 
 
Oocytes were selected for injection based upon color and division.  Approximately 41 
nL of RNA was oil hydraulically delivered with a glass capillary into the oocyte 
cytoplasm.  After injection, the oocytes were incubated at 19°C for three days in L-15, 
10 units/mL penicillin, 10 μg/mL streptomycin, and 10 μg/mL gentamycin. 
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After homogenizing oocytes in wash buffer (50 mM NaH2PO4, 50 mM NaCl, 5 mM 
EDTA, and 5 mM EGTA) containing protease inhibitors (5 mM benzamidine and 15 
mM iodoacetamide), protein was isolated by centrifugation for 30 minutes.  The 
supernatant was removed, and the pellet resuspended in extraction buffer + 2% Triton 
with protease inhibitors and rotated for 2 hours.  After further centrifugation, the 
supernatant protein extract was removed and used for immunoblotting and ligand 
binding assays. 
  
Immunoblotting 
After deglycosylation with PNGase F, the samples were denatured at 95ºC for 5 minutes 
and then run on a 12.5% acrylamide gel at room temperature and 30 mA.  Using a 
GENIE box, the protein was transferred to an Immun-Blot™ (Bio—Rad) polyvinylidene 
difluoride membrane at 30 volts for 30 minutes with 1X Western blot transfer buffer.  
The membrane was blocked overnight with gentle rocking at 4°C with dry milk in a 
PBS/0.05% TWEEN 20 solution.  After overnight incubation at 4°C and constant 
rocking with the primary antibody mAb 142 in block at a ratio of 1:10,000, the 
membrane was washed three times for an hour each with 1X PBS/0.05% TWEEN 
solution.  The membrane was incubated overnight at 4°C in a 1:5,000 ratio of secondary 
antibody, Goat anti Rat.  The wash steps were repeated and the membrane was 
developed on BioMax ML film using SuperSignal West Dura Extended Duration 
Substrate. 
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Ligand binding assays 
Immulon 4 HBX flat bottom polystyrene microtiter strips (Thermo Labsystems) were 
incubated overnight with 100 µL of 10 mM CAPSO containing 4 µg/mL mAb 142 at 
4°C in sealed plastic.  After washing three times with NaN3-PBS, they were incubated 
with 250 µL per well of PBS/NaN3-BSA blocker for approximately 3 hours at 4°C.  
Wells were then washed three times with wash buffer + 2% Triton X-100.  Protein 
extract was added to wells in duplicate in concentrations of ¼ oocyte and 1 oocyte, using 
extraction buffer + 2% Triton containing protease inhibitors to bring to a total 
concentration of 100 µL per well.  After incubation overnight at 4°C with constant 
rocking, wells were washed three times with wash buffer + 2% Triton.   
 
Twenty-five µCi of granisetron (Perkin Elmer Cat # NET-1030 BRL-43694, [9-methyl-
3H]-) was purchased at a concentration of 1.0 mCi/mL and with a specific activity of 
85.3 Ci/mmol.  Granisetron was added to wells at a concentration of 5 nM per well in 
100 µL of extraction buffer + 2% Triton following safety protocols for use of radioactive 
substances.  After incubation at 4°C overnight in sealed plastic, the wells were washed 
with wash buffer + 2% Triton and shaken at room temperature for 30 minutes with 120 
µL per well of 5% SDS + 25 mM DTT in extraction buffer + 2% Triton.  Liquid was 
removed from wells and placed in 3 mL of scintillation fluid (FISHER ScintiSafe Econo 
1 LSC-Cocktail) in 6 mL polyethylene vials (Packard BioScience).  Radioactivity was 
counted on a Packard 2500TR Liquid Scintillation Analyzer. 
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CHAPTER III 
RESULTS 
 
Production of plasmids 
To insert longer DNA sequences into plasmids, a modified QuikChange PCR strategy 
was used.  Primers were designed so that after incorporation of new sequence, ends of 
the DNA would overlap and a “pseudo-circle” could be formed.  This is important so 
that the DNA, which is linear after PCR, can be taken up and propagated as circular 
plasmids by bacteria.   
 
First, each primer contained approximately 30 bases complementary to the other primer 
in the pair.  This allows for creation of the “pseudo-circle.”  These 30 base pairs were 
“new,” but repeated in both primers.  Next, up to 20 new bases could be incorporated 
into each primer, allowing for about 40 new base pairs in all in the product DNA.  
Finally, each primer contained 30 base pairs complementary to the template DNA in 
order to facilitate binding to the template.  In this manner, it was possible to incorporate 
up to 70 new base pairs in the product DNA in one round of PCR.  The desired product 
was generated from about 50% of the clones. 
 
The Kozak sequence has been shown to be a significant contributing factor to 
optimization of protein expression (32).  The Kozak sequence for Xenopus (ACC) was 
successfully inserted through the use of PCR mutagenesis.   
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Using two additional rounds of PCR, the N-terminal mAb 142 epitope tag, surrounded 
on either side by a “linker” region, was inserted into the ECD.  Each linker region 
consisted of an alanine, glycine, and serine segment repeated six times.  The linker 
regions were incorporated to promote flexibility of the epitope tag binding region in the 
ECD, thereby improving antibody binding and reducing possible interference with the 
ligand binding domain.   
 
Epitope binding regions inserted in the C-terminus of 5-HT3R constructs have been 
determined to interfere with ligand binding in truncated constructs despite abundant 
protein production.  For this reason, a final round of PCR mutagenesis was performed 
and a stop codon was inserted directly preceding the two C-terminal copies of the mAb 
142 epitope tag binding region present in the starting receptor.   
 
For all constructs, the PCR product with the highest yield of DNA at the appropriate 
base pair length (4686 to 4774 base pairs, depending on the construct) was chosen for 
digestion with Dpn I to degrade parent DNA (Figure 3). 
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FIGURE 3. PCR products chosen for Dpn I digestion.  Desired band is marked with a white arrow.  
DNA ladders from each respective gel are shown.  A. First round of PCR to insert linker region and 
mAb142 epitope. B. Second round inserting linker and epitope. C. Insertion of Kozak fragment. D. 
Insertion of stop codon before C-terminal epitope tags. E. 5-HT3M1. F. 5-HT3970V. G. 5-HT3M1M2. H. 
5-HT3ECD. 
 
 
Extraction after running on an agarose gel allowed for purification of the product; a 
representation of a Dpn I digested sample is shown with the band marked which was 
extracted (Figure 4).  
 
DNA amplification in bacteria 
Colonies grown from dilutions of 1:1, 1:10, and 1:100 of the transformed bacteria were 
chosen based on size and resolution from other colonies for plasmid DNA extraction via 
mini-prep (Figure 5).  Colonies were round and pale white. 
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FIGURE 4. Extraction of Dpn I digested sample.  Extracted band from digested sample of second round 
of PCR to insert linker region and mAb142 epitope.  Chosen band is marked with a white arrow. 
 
 
 
FIGURE 5.  Plates of bacteria transformed with the 5-HT3M1 plasmid.  A. Colonies grown from a 1:1 
dilution of transformed bacterial solution, B. a 1:10 dilution, and C. a 1:100 dilution.  For bacteria 
transformed with the 5-HT3M1 plasmid, all colonies were selected from plate C.  Colonies were chosen 
based on regularity of shape and resolution from other colonies. 
  
A B
C
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Double digests performed with EcoRV and Xho I at 37°C with Buffer 3 + BSA 
confirmed presence of correct plasmid based on prediction of band size; correct plasmids 
from mini-preps were sequenced (Figure 6).  
 
 
 
FIGURE 6. Double digest of mini-preps for sequencing.  Shown is the double digest of 5-HT3Full after 
the first round of PCR.  DNA from lanes 2,3,4, and 5 were sequenced to confirm correct DNA.  Bands 
with lengths of 886 and 3882 base pairs confirm the presence of 5-HT3Full. 
 
 
Double and single digests were performed on midi-prep products with EcoRV and/or 
Xho I to confirm presence of correct DNA and to determine concentration (Figure 7).  
DNA yield was sufficient for all constructs and yielded approximately 50 µL DNA at 
concentrations in the range of 0.08 µg/µL to 0.500 µg/µL. 
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FIGURE 7. Double and single digests of midi-prep.  Shown are the single digest of 5-HT3Full with 
EcoRV after insertion of the Kozak sequence (lane 1) and the double digest with EcoRV and Xho I to 
confirm correct DNA plasmid (lane 2).  The concentration was estimated to be 0.08 µg/µL based on 
comparison with the DNA marker. 
 
 
Protein expression 
DNA was successfully linearized and RNA produced from all constructs (Figure 8).   
After injection of RNA in oocytes and production and extraction of protein, the 
supernatant protein extract was removed and used for immunoblotting and ligand 
binding assays.  The desired protein was shown by Western blot analysis to be 
successfully produced from all constructs (Figure 9). 
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FIGURE 8. RNA production from construct DNA.  A. RNA production from linearized DNA using an 
SP6 mMessage mMachine Kit.  From left to right are 5HT3Full, 5HT3M1, 5HT3ECD, 5HT3M1M2, 
5HT3970V, and the control, 5HT3M1 C-term 2x mAb 142 (a construct containing 2 copies of a C-terminal 
epitope tag, previously determined to bind antibody for Western blotting but to have limited ligand 
binding activity).  B. Linear DNA from incubation with EcoRI.  From left to right are 5HT3Full, 5HT3M1, 
5HT3970V, 5HT3ECD, 5HT3M1M2, and control. 
 
 
 
 
 
FIGURE 9. Immunoblot of protein from constructs.  Protein was expressed successfully for all 
constructs in yields comparable to that of the full length.  Shown is protein from uninjected oocytes (1), 
α4M1 2x142 + βM1236 control (2), 5-HT3M1 2xmAb142 C-term control (3), 5-HT3Full (4), 5-HT3M1(5), 
5-HT3M1M2 (6), 5-HT3970V (7), and 5HT3ECD (8).  Protein from 1/6 oocyte (3.37 µL) was loaded for 
all samples except for uninjected (1 oocyte at 20.2 µL). 
75
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Western blots exhibited a minimum amount of background noise.  Because the 
additional proteins did not move as far as the target proteins, they were surmised to have 
originated due either to incomplete denaturation or to insufficient deglycosylation.  No 
extraneous proteins were observed in the lane containing the uninjected oocytes.  This 
supports the conclusion that the extra bands were not due to contamination or 
insufficient purification of the extract from the oocytes.  Two controls were also run on 
the Western blot and similarly exhibited the extra bands.  Because of these results, it is 
all the more likely that the variations in protein size are due to incomplete denaturation 
or deglycosylation. 
 
Ligand binding 
Previous studies with the nAChR have shown that ECD models truncated before M1 
exhibit compromised ligand binding, but those truncated after M1 exhibit comparable 
ligand binding to that of the native receptor (26).  Because of this, it was anticipated that 
the 5-HT3ECD construct would similarly exhibit highly reduced ligand binding, but that 
the 5-HT3M1 construct would bind to granisetron.   
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FIGURE 10. Binding of granisetron to construct protein.  None of the constructs displayed ligand 
binding profiles comparable to that of the full-length.  The 5-HT3M1 2xmAb142 C-term construct was 
used as the control.  Moles of bound granisetron was determined as an average of moles bound per oocyte 
from assays run in duplicate in concentrations of ¼ and 1 oocyte. 
 
 
As predicted, the 5-HT3ECD construct did not show significant binding compared to the 
5-HT3Full construct (Figure 10).  Negligible binding to granisetron of the 5-HT3M1 
construct, however, was unexpected.  This finding points to the essential function of 
other portions of the receptor or to a conformational change or other interference of the 
ligand binding site on exposure of M1.  
 
Amino acid residues located in a transmembrane spanning segment of a protein are 
generally characterized by having uncharged side chains; this promotes stability in the 
hydrophobic interior of a membrane’s lipid bilayer.  The middle region of the first 
transmembrane domain of the 5-HT3R contains aspartic acid, an acidic residue.  Because 
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the mutation of a corresponding aspartic acid residue in M1 of the nAChR to a nonpolar 
amino acid enhances ligand binding, it was proposed that this acidic aspartic acid residue 
may interact with another basic residue localized elsewhere in a transmembrane domain 
of the protein for neutralizing the negative charge of the aspartic acid side chain and 
efficient assembly of the subunits.  A likely basic residue is K281 near the start of M2.  
This motivated design of the 5-HT3M1M2 and 5-HT3970V constructs.  It was proposed 
that if a corresponding basic residue (such as K281) interacts with M1 in the native 
conformation of the receptor, the 5-HT3M1M2 construct would exhibit successful 
binding.  Mutation of the aspartic acid to a nonpolar residue, such as valine in the 
construct 5-HT3970V, would eliminate the need for interaction with another residue, 
allowing for increased binding to granisetron.  
  
Significant binding was not observed for the 5-HT3M1M2 construct, however.  Though 
minimal binding was recorded for the 5-HT3970V construct, there was not enough 
evidence to sustain the hypothesis that exposure of the aspartic acid residue in M1 
causes interference with the ligand binding site (Figure 10). 
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CHAPTER IV 
 
SUMMARY AND CONCLUSIONS 
 
Unlike the nAChR, truncation after the first transmembrane domain of the 5-HT3R does 
not yield a receptor with comparable ligand binding properties to that of the full length 
receptor. Because of the amount of homology between the nAChR and the 5-HT3R, it 
was expected that, as for the nAChR, truncating the receptor before the start of M1 
would not yield an ECD model with an at least partially equivalent ligand binding 
profile to that of the native receptor, but that truncation after M1 would produce a 
receptor with a similar binding profile.   
 
An aspartic acid situated in the middle of M1 is present in both the 5-HT3R and the 
nAChR.  Considering that mutation of the aspartic acid residue to an uncharged residue 
in a truncated nAChR leads to increased binding, a suitable hypothesis was able to be 
proposed concerning the lack of increased binding for similarly truncated 5-HT3R 
constructs: (1) that this charged amino acid, positioned in the midst of a hydrophobic 
region, was either interacting with another residue and had an important role in creating 
a certain conformation for the formation of a ligand binding site, or (2) that by removing 
a residue which in the native conformation was interacting with the aspartic acid, the 
exposed residue was producing conformational changes inhibiting the binding site.  
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To determine the extent of the influence of this particular amino acid in the functioning 
of the native receptor, a construct was created including M2, which contains a basic 
lysine residue, in addition to M1.  The inclusion of M2 would help restore the binding 
site, if this was, in fact, the role of the aspartic acid in question.  It must be noted, 
however, that by truncating the receptor after M2, a negative charge from the carboxyl 
group of the terminal amino acid may have been introduced into the vicinity of the 
binding site, causing unintentional, ancillary interactions.  Perhaps a construct designed 
that places the terminal amino acid within the membrane would lead to improved 
binding to granisetron of the 5-HT3M1M2 construct. 
 
Another construct, substituting the aspartic for a nonpolar amino acid, valine, also was 
created.  In this construct, the removal of the charge from M1 would facilitate the 
formation of the binding site if the exposed negative charge from the aspartic acid buried 
in the membrane was the cause of aberrant folding of the subunit and reduced ligand 
binding. 
 
Surprisingly, none of the constructs (excepting the full length construct) exhibited 
appreciable ligand binding.  Though the 5-HT3970V construct did show minimal 
binding, it was nevertheless severely reduced compared to that of the full length 
construct.  From this it must be concluded that either the exposure of the aspartic acid 
residue does not significantly affect the binding abilities of the receptor as it does in the 
nAChR, or the more likely explanation, that the absence of a distinct, vitally important 
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region present in the native receptor 5-HT3R is severely inhibiting the ligand binding 
capacity of the receptor. 
 
It has been proposed that the C-terminus of the 5-HT3R performs a critical role in the 
function of the native receptor.  In their search to identify the minimum number of 
residues needed to create the binding site, Butler et. al have emphasized the role of the 
short extracellular 5-HT3R C-terminus in the formation of a functional, homomeric 5- 
HT3A receptor, mostly in subunit folding and maturation (34).  Deletion of the terminal 
alanine led to 4% ligand binding compared to the wild type receptor.  Mutations of this 
alanine to other small, nonpolar amino acids such as valine, glycine, and leucine also 
reduced radioligand binding.  Substitution to alanine of the two amino acids immediately 
preceding the terminal alanine (glutamine and tyrosine) did not inhibit binding.  A role 
for the C-terminus in “locking” the receptor in a mature binding conformation, through 
interaction of the tyrosine with the Cys-loop of the N-terminus, has also been proposed 
by Pons et. al (35).  This group further postulates that the mature conformation, by 
concealing a retention signal present in M1, allows for proper export of the receptor to 
the cell surface.  
 
Due to the role of the 5-HT3R in a large variety of pathologies, including cytotoxic drug-
evoked emesis, schizophrenia, Parkinson disease, addiction, and nociception, the 
elucidation of its structure remains an invaluable objective.  Though these findings did 
not clarify a role for the aspartic acid in the midst of M1, further work in this direction 
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would be beneficial.  Inclusion of part of the C-terminus may prove to have drastically 
beneficial effects on ligand binding profiles in later studies.  With this addition, it may 
be possible to revisit the question of the importance of M1 to receptor function.  This 
would be a considerable contribution towards the design of a shorter, more soluble ECD 
model with which a high resolution structure of the 5-HT3R may finally be attained. 
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